remlarsen

Remlarsen is a synthetic microRNA mimic (promiR) of microRNA-29b (miR-29b), developed as an antifibrotic agent. It functions by mimicking and agonizing miR-29b activity, thereby repressing the expression of multiple collagens and other extracellular matrix proteins involved in fibrosis. Remlarsen has been investigated for its potential to prevent or reduce fibrotic scar formation in skin (such as keloids and hypertrophic scars), cutaneous fibrosis, corneal fibrosis following injury or ulceration, and other fibrotic conditions including cardiac, renal, hepatic, pulmonary, and ocular fibrosis. The drug was developed by Viridian Therapeutics (formerly miRagen Therapeutics) in collaboration with Yale University and originated at the University of Texas Southwestern Medical Center. Clinical trials included Phase 2 studies for prevention or reduction of keloid formation; however, development has been discontinued for all indications[2][3][4][5][8].

Brand names

remlarsen

Other names

miR-29b mimicmiR29b mimicmiR 29b mimicpromiR to microRNA 29b